ClinicalTrials.gg
RecruitingNCT07094113Updated Jul 30, 2026

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of AMG 410 and Pembrolizumab in KRAS Altered Advanced or Metastatic Solid Tumors, sponsored by Amgen. Recruiting at 39 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
434
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen — 2 open to participants now, 7 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Amgen.

Planned enrollment
5th of 31
434 · median 145
Started
2025
with 1 other
Phase 1
8 of 40
1 open now
Registered
39th of 40
by date

Among the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, this one is the 5th largest by planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2025, is one of 8 in phase 1, and was the 39th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, or all of them as a file.
02

Study summary

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in participants with advanced or metastatic solid tumors harboring KRAS alterations.

This is a dose-escalation study in which participants will be assigned to multiple dose levels (DLs) of AMG 410, either as monotherapy or in combination with other agents, followed by expansion cohorts. The goal is to determine the Maximum Tolerated Dose (MTD)-the highest dose with acceptable safety and manageable side effects-or the Recommended Phase 2 Dose (RP2D) of AMG 410 in adult participants with KRAS-altered advanced or metastatic solid tumors.

Read the detailed description

This is a multicenter, multinational, open-label Phase 1/1b study designed to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of AMG 410 in adult participants with advanced or metastatic solid tumors characterized by KRAS alterations.

The study will begin with a dose-escalation phase, during which AMG 410 will be administered orally, either as monotherapy or in combination with other agents. Dose escalation will follow a model-based approach to identify the MTD or RP2D.

Following dose escalation, additional expansion cohorts may be enrolled at selected dose levels to further characterize the safety profile, PK/PD relationships, and preliminary efficacy in specific tumor types or molecular subgroups.

Participants will continue treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria. The maximum duration of AMG 410 administration in this study is 3 years.

03

Conditions studied

  • KRAS Altered Advanced or Metastatic Solid Tumors

Keywords

  • Non-small cell lung cancer
  • NSCLC
  • Colorectal cancer
  • CRC
  • Pancreatic ductal adenocarcinoma
  • PDAC
  • AMG 410
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years (or > legal age within the country if it is older than 18 years).
  2. documented, locally-advanced or with any missense mutation in the KRAS gene or evidence of KRAS amplification using an analytically validated KRASWT amplification assay.
  3. Participants must have no standard of care treatment options or have actively refused such therapy.
  4. Able to swallow and retain per oral administered study treatment.
  5. (ECOG) Performance Status of 0 or 1.
  6. Disease measurable as defined by Version 1.1 (RECIST v1.1), as determined by the site investigator.
  7. Adequate organ function.
  8. Archival (formalin-fixed, paraffin-embedded [FFPE]) tumor tissue or block collected within 5 years before screening must be available. Participants without archived tumor tissue may undergo tumor before AMG 410 dosing (Day1).

Exclusion criteria

Exclusion Criteria:

  1. Untreated symptomatic central nervous system or .
  2. Uncontrolled pleural effusion and/or ascites.
  3. History of other within the past 5 years.
  4. Active systemic infection or symptoms that indicate an acute and/or uncontrolled infection requiring IV antibiotics within 7days prior to the first dose of study treatment.
  5. History of arterial or venous thrombosis (eg, stroke, , pulmonary embolism, or deep vein thrombosis).
  6. Live and are prohibited within 28 days prior to the first dose of study treatment.
  7. History of solid organ transplant.
  8. Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, hormonal therapy, or agent) within 28 days of first dose of study treatment.
  9. Presence or history of any of the following viral infections: , , , and active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  10. Toxicities from prior anti-tumor therapy (including radiotherapy) not having improved to at least (CTCAE) version 5.0 grade 1.
  11. Therapeutic or palliative radiation therapy within 2 weeks of first dose of study treatment.
  12. Major surgery within 28 days of first dose of study treatment.
  13. History or evidence of any other disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
434 participants (estimated)

Study arms

  • Experimental
    Part 1: Monotherapy Dose Exploration

    Participants will receive escalating doses of AMG 410.

    Drug: AMG 410

  • Experimental
    Part 1: Food Effect Substudy Cohort

    A food effect substudy will be conducted. During the substudy, participants will receive AMG 410 under fasted and fed conditions.

    Drug: AMG 410

  • Experimental
    Part 1: China-specific Cohort

    Participants identified through regionally approved molecular KRAS testing will receive AMG 410.

    Drug: AMG 410

  • Experimental
    Part 2: Monotherapy Dose Expansion

    Monotherapy dose expansion of AMG 410 may proceed in KRAS altered tumors in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and other KRAS altered tumor types.

    Drug: AMG 410

  • Experimental
    Part 3a: Combination Therapy Dose Exploration and Dose Expansion

    Part 3a allows for AMG 410 dose exploration and expansion in combination with pembrolizumab in KRAS altered advanced or metastatic solid tumors.

    Drug: AMG 410 · Drug: Pembrolizumab

  • Experimental
    Part 3b: Combination Therapy Dose Exploration and Dose Expansion

    Part 3b allows for AMG 410 dose exploration and expansion in combination with panitumumab in advanced or metastatic CRC and/or PDAC.

    Drug: AMG 410 · Drug: Panitumumab

Interventions

  • DrugAMG 410

    Administered as an oral tablet.

  • Administered as an intravenous (IV) infusion.

  • Administered as an IV infusion.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities (DLTs)

    Time frame: Up to 28 days

  2. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Clinically significant changes in safety assessments (vital signs, electrocardiograms \[ECGs\], and clinical laboratory tests) are to be reported as adverse events.

    Time frame: Up to approximately 3 years

  3. Number of Participants with Serious Adverse Events (SAEs)

    Clinically significant changes in safety assessments (vital signs, ECGs, and clinical laboratory tests) are to be reported as adverse events.

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Maximum Concentration (Cmax) of AMG 410

    Time frame: Up to 85 days

  2. Time to Reach Cmax (Tmax) of AMG 410

    Time frame: Up to 85 days

  3. Area Under the Concentration-time Curve (AUC) Over the Dosing Interval of AMG 410

    Time frame: Up to 85 days

  4. Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Up to approximately 3 years

  5. Clinical Benefit per RECIST v1.1

    Time frame: Up to approximately 3 years

  6. Duration of Response (DoR) per RECIST v1.1

    Time frame: Up to approximately 3 years

  7. Time to Response (TTR) per RECIST v1.1

    Time frame: Up to approximately 3 years

  8. Progression-free Survival (PFS) per RECIST v1.1

    Time frame: Up to approximately 3 years

  9. Overall Survival (OS)

    Time frame: Up to approximately 3 years

  10. Food Effect Substudy Cohort: Cmax of AMG 410 in the Fed and/or Fasted State

    Time frame: Up to 24 days

  11. Food Effect Substudy Cohort: Tmax of AMG 410 in the Fed and/or Fasted State

    Time frame: Up to 24 days

  12. Food Effect Substudy Cohort: AUC Over the Dosing Interval of AMG 410 in the Fed and/or Fasted State

    Time frame: Up to 24 days

  13. Change From Baseline in Tumor Phosphorylated Extracellular Signal Regulated Kinase (pERK)

    Time frame: Baseline up to approximately 3 years

07

Study locations

39 of 39 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2028, 32 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 32 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Jul 30, 2025
StartActual
Jul 31, 2025
Primary completionEst.
Apr 18, 2028
CompletionEst.
Apr 20, 2031
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07094113
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 30, 2025
Start date
Jul 31, 2025
Primary completion
Apr 18, 2028 (estimated)
Completion
Apr 20, 2031 (estimated)
Last update
Jul 30, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion